nanovibronix inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology. the company's patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. this unique development may be utilized for a variety of medical requiring low cost therapeutic ultrasound applications. the company's patch based product diagnosis, painshield®, carries an fda clearance. nanovibronix catheter based products include the cathbottm . nanovibronix inc. is located in elmsford, ny. its subsidiary, nanovibronix ltd. is located in nesher, israel.
Company profile
Ticker
NAOV
Exchange
Website
CEO
Brian Murphy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
Nano Vibronix Inc, Nano Vibronix, Inc.
SEC CIK
NAOV stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
17 Jan 24
8-K
Other Events
17 Jan 24
8-K
Changes in Registrant's Certifying Accountant
11 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
DEFA14A
Additional proxy soliciting materials
29 Nov 23
DEF 14A
Definitive proxy
29 Nov 23
8-K
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
28 Nov 23
8-K
Other Events
21 Nov 23
8-K
NanoVibronix Issues Letter to Shareholders
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 6 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 192.51 mm |
Total shares | 3.21 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Packer Paul | 1.67 mm | $1.28 mm |
Hirschman Orin | 771.46 k | $589.00 k |
Alpha Capital Anstalt | 645.72 k | $493.00 k |
Armistice Capital | 29.02 k | $57.18 mm |
Vanguard | 28.42 k | $55.98 mm |
Geode Capital Management | 14.46 k | $28.49 mm |
VIRT Virtu Financial | 13.78 k | $27.00 k |
HRT Financial | 13.12 k | $25.00 k |
AFSIP Amtrust Financial Services | 12.41 k | $24.44 mm |
UBS UBS Group AG - Registered Shares | 8.87 k | $17.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 24 | Maria Schroeder | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.9 | 16,667 | 15.00 k | 16,667 |
23 Jan 24 | Michael Ferguson | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.9 | 16,666 | 15.00 k | 16,666 |
23 Jan 24 | Martin M Goldstein | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.9 | 16,667 | 15.00 k | 16,667 |
23 Jan 24 | Aurora Cassirer | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.9 | 16,667 | 15.00 k | 16,667 |
23 Jan 24 | Thomas Mika | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.9 | 16,666 | 15.00 k | 16,666 |